The risk of non-AIDS defining events is lower in ART-naive HIV controllers than in normal progressors on suppressive ART

• Published in: Clinical infectious diseases
• Main Authors: Groenendijk, Albert L, Miranda Afonso, Pedro, Wit, Ferdinand, Blaauw, Martinus J T, van Eekeren, Louise E, Otten, Twan, Vos, Wilhelm A J W, Vadaq, Nadira, Dos Santos, Jéssica C, van Lunzen, Jan, van der Ven, Andre, Rokx, Casper, Verbon, Annelies
• Format: Journal Article
• Language: English
• Published: United States 29.08.2024
• Subjects: elite controllers; ART; non-AIDS defining events; HIV controllers
• ISSN: 1537-6591
• DOI: 10.1093/cid/ciae440

We aimed to compare the non-AIDS events (nADE) risk between normal progressors using ART (NP-ART) and people with HIV (PWH) that naturally control HIV infection (HIV controllers), as well as the outcomes after ART in HIV controllers on nADE. The primary endpoint was major nADE defined as the composite of cardiovascular disease, non-AIDS malignancy or all-cause mortality, whichever came first.. The role of ART in HIV controllers was assessed as a time-varying covariate. We included 1007 ART-naive HIV controllers (of which 60 elite controllers), 1510 Early-ART (<6 months after negative HIV test) and 15437 NP-ART (reference group), contributing 3813, 11,060 and 160,050 years of follow-up, respectively. HIV controllers had lower risk of the primary endpoint (HR 0.55, 95%CI 0.38-0.81, P = 0.0023), all-cause mortality (Adjusted Hazard ratio [aHR]: 0.45, 95% confidence interval [CI] 0.25-0.79, P = 0.0054), cardiovascular disease (aHR 0.47, 95%CI 0.22-0.99, P = 0.046) , but not non-AIDS malignancy (aHR 0.74, 95%CI 0.41-1.35, P = 0.33) than NP-ART. Among HIV controllers, each log10 lower baseline viral load further decreased the risk of nADE (aHR 0.54, 95% CI 0.29-0.99, P = 0.045). ART in HIV controllers did not reduce the risk of any nADE (aHR 1.22, 95% CI 0.66-2.29, P = 0.53). We found a lower risk of nADE in HIV controllers than NP-ART, especially in those with low plasma viral loads. Initiation of ART did not alter the nADE risk in HIV controllers. Our findings help clinicians to decide on prescribing ART in HIV controllers.